Vident Investment Advisory LLC Has $2.59 Million Stake in Nektar Therapeutics (NKTR)

Vident Investment Advisory LLC grew its holdings in Nektar Therapeutics (NASDAQ:NKTR) by 49.9% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 52,994 shares of the biopharmaceutical company’s stock after acquiring an additional 17,640 shares during the quarter. Vident Investment Advisory LLC’s holdings in Nektar Therapeutics were worth $2,588,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. Macquarie Group Ltd. boosted its position in shares of Nektar Therapeutics by 966.0% in the second quarter. Macquarie Group Ltd. now owns 165,000 shares of the biopharmaceutical company’s stock valued at $8,057,000 after acquiring an additional 149,522 shares during the period. World Asset Management Inc lifted its position in Nektar Therapeutics by 16.6% in the second quarter. World Asset Management Inc now owns 10,646 shares of the biopharmaceutical company’s stock worth $520,000 after purchasing an additional 1,513 shares during the period. MetLife Investment Advisors LLC lifted its position in Nektar Therapeutics by 72.3% in the first quarter. MetLife Investment Advisors LLC now owns 115,385 shares of the biopharmaceutical company’s stock worth $12,261,000 after purchasing an additional 48,428 shares during the period. Gateway Investment Advisers LLC bought a new position in Nektar Therapeutics in the second quarter worth $342,000. Finally, Riverhead Capital Management LLC lifted its position in Nektar Therapeutics by 241.0% in the second quarter. Riverhead Capital Management LLC now owns 7,134 shares of the biopharmaceutical company’s stock worth $348,000 after purchasing an additional 5,042 shares during the period. 92.20% of the stock is owned by institutional investors.

Shares of NASDAQ NKTR opened at $51.76 on Tuesday. Nektar Therapeutics has a 52-week low of $22.72 and a 52-week high of $111.36. The firm has a market cap of $10.51 billion, a price-to-earnings ratio of -94.20 and a beta of 2.39. The company has a debt-to-equity ratio of 0.13, a current ratio of 19.67 and a quick ratio of 19.55.

Nektar Therapeutics (NASDAQ:NKTR) last announced its earnings results on Wednesday, August 8th. The biopharmaceutical company reported $5.33 earnings per share for the quarter, beating the Zacks’ consensus estimate of $5.22 by $0.11. Nektar Therapeutics had a return on equity of 174.70% and a net margin of 65.69%. The company had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same period last year, the company posted ($0.39) earnings per share. The firm’s quarterly revenue was up 3043.7% compared to the same quarter last year. As a group, sell-side analysts predict that Nektar Therapeutics will post 3.77 earnings per share for the current year.

NKTR has been the subject of several research reports. HC Wainwright cut Nektar Therapeutics from a “buy” rating to a “neutral” rating and set a $54.00 target price for the company. in a research report on Monday, June 11th. BidaskClub raised Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, June 19th. ValuEngine cut Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, June 26th. Zacks Investment Research raised Nektar Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 price objective for the company in a report on Monday, July 16th. Finally, Piper Jaffray Companies set a $125.00 price objective on Nektar Therapeutics and gave the company a “buy” rating in a report on Wednesday, July 25th. Three equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. Nektar Therapeutics has a consensus rating of “Buy” and an average price target of $82.91.

In other news, Director Dennis L. Winger sold 34,250 shares of the firm’s stock in a transaction on Tuesday, August 14th. The stock was sold at an average price of $60.60, for a total value of $2,075,550.00. Following the completion of the sale, the director now directly owns 59,875 shares in the company, valued at $3,628,425. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Dennis L. Winger sold 30,000 shares of Nektar Therapeutics stock in a transaction dated Tuesday, August 21st. The stock was sold at an average price of $59.96, for a total value of $1,798,800.00. Following the completion of the sale, the director now owns 57,750 shares of the company’s stock, valued at $3,462,690. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 96,000 shares of company stock valued at $5,825,680. 4.31% of the stock is currently owned by corporate insiders.

About Nektar Therapeutics

Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.

See Also: Average Daily Trade Volume – What You Need to Know

Institutional Ownership by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply